Vincent Guerlavais

Stapled α−helical peptide drug development: A potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy

Yong S. Chang, Bradford Graves, Vincent Guerlavais et al. · Proceedings of the National Academy of Sciences · 2013 · 653 citations · Full text

Dual inhibition of MDMX and MDM2 as a therapeutic strategy in leukemia

Luis A. Carvajal, Daniela Ben Neriah, Adrien Senecal et al. · Science Translational Medicine · 2018 · 243 citations · Full text

Chemoprevention Strategy, Mixed-phenotype Acute Leukemia, Therapeutic Strategy +23

Pharmacologic Activation of p53 Triggers Viral Mimicry Response Thereby Abolishing Tumor Immune Evasion and Promoting Antitumor Immunity

Xiaolei Zhou, Madhurendra Singh, Gema Sanz et al. · Cancer Discovery · 2021 · 167 citations · Full text

Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type <i>TP53</i>

Mansoor N. Saleh, Manish R. Patel, Todd M. Bauer et al. · Clinical Cancer Research · 2021 · 135 citations · Full text

Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical models

Samuel Y. Ng, Noriaki Yoshida, Amanda L. Christie et al. · Nature Communications · 2018 · 111 citations · Full text